Syfovre (pegcetacoplan) — “Slowing the Fade: The First Approved Drug to Slow Geographic Atrophy — Promise, Patents, and Problems”
Below is an in-depth, evidence-based article on Syfovre (active substance pegcetacoplan) that covers: developer and regulatory status, the IP/patent picture, the drug’s benefits, limitations,…
Read more →Comirnaty — “mRNA on the Frontline: How Tozinameran Changed Vaccination”
Executive summary (one line) Comirnaty (tozinameran, BNT162b2) is the Pfizer–BioNTech mRNA COVID-19 vaccine that transformed pandemic response through very high clinical efficacy, rapid global…
Read more →Imjudo (tremelimumab) — “Turning up the Heat on Cancer: The Promise and Price of CTLA-4 Blockade”
Below is an in-depth, evidence-based article about Imjudo (active ingredient tremelimumab): who developed it, the intellectual-property picture, clinical benefits, limitations, and the main safety…
Read more →Nintedanib Accord: Europe’s First Generic Nintedanib—What to Know About Origins, Patents, Benefits, Risks, and Trial Safety
Short take: Nintedanib Accord is the EU-authorised generic of Boehringer Ingelheim’s nintedanib (brand: Ofev). It slows lung-function decline across several fibrosing interstitial lung diseases…
Read more →Keytruda (pembrolizumab): a deep-dive
What it is. Keytruda is Merck & Co.’s (MSD outside the US/Canada) humanized IgG4 monoclonal antibody that blocks PD-1, releasing an immune “brake” so…
Read more →Sixmo – A Long-Acting Implant for Opioid Dependence
What Is Sixmo? Sixmo is a buprenorphine hydrochloride implant designed as a long-lasting substitution treatment for opioid dependence. It is intended for clinically stable…
Read more →